REFERENCES
1. Yang K, Yang X, Yin P, Zhou M, Tang Y. Temporal trend and attributable risk factors of Alzheimer’s disease and other dementias burden in China: findings from the Global Burden of Disease Study 2021. Alzheimers Dement. 2024;20:7871-84.
3. Rentz DM, Aisen PS, Atri A, et al. Benefits and risks of FDA‐approved amyloid‐targeting antibodies for treatment of early Alzheimer’s disease: navigating clinician-patient engagement. Alzheimers Dement. 2024;20:8162-71.
4. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023;388:9-21.
5. Sims JR, Zimmer JA, Evans CD, et al. ; Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023;330:512.
6. Márquez F, Tarraf W, Kuwayama S, et al. Subjective cognitive decline and cognitive change among diverse middle‐aged and older Hispanic/Latino adults: results from the Study of Latinos-Investigation of Neurocognitive Aging (SOL‐INCA). Alzheimers Dement. 2024;20:7715-28.
7. Jessen F, Amariglio RE, van Boxtel M, et al. ; Subjective Cognitive Decline Initiative (SCD‐I) Working Group. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease. Alzheimers Dement. 2014;10:844-52.
8. Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement. 2024;20:5143-69.
9. Shao K, Hu X, Kleineidam L, et al. ; DELCODE study group. Amyloid and SCD jointly predict cognitive decline across Chinese and German cohorts. Alzheimers Dement. 2024;20:5926-39.
10. Jessen F, Amariglio RE, Buckley RF, et al. The characterisation of subjective cognitive decline. Lancet Neurol. 2020;19:271-8.
11. Rabin LA, Smart CM, Amariglio RE. Subjective cognitive decline in preclinical Alzheimer’s disease. Annu Rev Clin Psychol. 2017;13:369-96.
12. Kang M, Li C, Mahajan A, et al. Subjective cognitive decline plus and longitudinal assessment and risk for cognitive impairment. JAMA Psychiatry. 2024;81:993-1002.
13. Pike KE, Cavuoto MG, Li L, Wright BJ, Kinsella GJ. Subjective cognitive decline: level of risk for future dementia and mild cognitive impairment, a meta-analysis of longitudinal studies. Neuropsychol Rev. 2022;32:703-35.
14. Baumeister H, Gellersen HM, Polk SE, et al. ; DELCODE study group. Disease stage-specific atrophy markers in Alzheimer’s disease. Alzheimers Dement. 2025;21:e70482.
15. Jiang X, Zhang M, Yan C, et al. Brain Topological Changes in Subjective Cognitive Decline and Associations with Amyloid Stages. J. Neurosci. 2025;45:e2310242025.
16. Wang X, Huang W, Su L, et al. Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer’s disease. Mol Neurodegener. 2020;15:55.
17. Hong YJ, Choi SH, Kim S, et al. ; CoSCo study group. Cognitive and neurodegenerative trajectories of subjective cognitive decline according to baseline biomarkers: results of the CoSCo study. Alzheimers Dement. 2025;21:e14473.
18. Zlatar ZZ, Tarraf W, González KA, et al. Subjective cognitive decline and objective cognition among diverse U.S. Hispanics/Latinos: results from the Study of Latinos-Investigation of Neurocognitive Aging (SOL‐INCA). Alzheimers Dement. 2022;18:43-52.
19. Thomas KR, Edmonds EC. Objective criteria for subtle cognitive decline in aging and preclinical Alzheimer disease: a systematic review. Neurology. 2025;104:e213536.
20. Cheng GR, Liu D, Huang LY, et al. Prevalence and risk factors for subjective cognitive decline and the correlation with objective cognition among community‐dwelling older adults in China: Results from the Hubei memory and aging cohort study. Alzheimers Dement. 2023;19:5074-85.
21. Schneider LS, Freiesleben SD, van Breukelen G, et al. Linking higher amyloid beta 1-38 (Aβ(1‐38)) levels to reduced Alzheimer’s disease progression risk. Alzheimers Dement. 2025;21:e14545.
22. Chae H, Kim H, Kim Y, Ji H, Oh EJ, Yang DW. Diagnostic performance of eight blood-based biomarkers in a well-characterized Korean cohort of preclinical Alzheimer’s disease. Ann Lab Med. 2025;45:428-36.
23. Giacomucci G, Crucitti C, Ingannato A, et al. The two cut‐offs approach for plasma p‐tau217 in detecting Alzheimer’s disease in subjective cognitive decline and mild cognitive impairment. Alzheimers Dement. 2025;17:e70116.
24. Mengel D, Soter E, Ott JM, et al. ; DELCODE study group. Blood biomarkers confirm subjective cognitive decline (SCD) as a distinct molecular and clinical stage within the NIA-AA framework of Alzheimer’s disease. Mol Psychiatry. 2025;30:3150-9.
25. Shokouhi S, Conley AC, Baker SL, et al. The relationship between domain-specific subjective cognitive decline and Alzheimer’s pathology in normal elderly adults. Neurobiol Aging. 2019;81:22-9.
26. Wei M, Yu X, Hu S, et al. Differences of longitudinal plasma biomarkers between single memory domain and multidomain subjective cognitive decline: evidence from SILCODE. J Alzheimers Dis. 2025;103:1060-74.
27. Levine TF, Allison SL, Dessenberger SJ, Head D. ; Alzheimer’s Disease Neuroimaging Initiative. Clinical utility of self- and informant-reported memory, attention, and spatial navigation in detecting biomarkers associated with Alzheimer disease in clinically normal adults. J Int Neuropsychol Soc. 2024;30:232-43.
28. Xie XY, Huang LY, Cheng GR, et al. Association between long-term exposure to ambient air pollution and the risk of mild cognitive impairment in a Chinese urban area: a case-control study. J Alzheimers Dis. 2024;98:941-55.
29. Zhang J, Liu D, Liu J, et al. Effects of self-managed lifestyle behavioral changes on cognitive impairment control in Chinese older adults: a population-based prospective study. Transl Psychiatry. 2025;15:165.
30. Liu J, Liu D, Xie X, et al. Association between home dwelling situations, neighborhood social interactions, and subjective cognitive decline plus among older adults: a cross-sectional study. J Alzheimers Dis. 2025;104:1125-35.
31. Li L, Cheng GR, Liu D, et al. The Hubei Memory and Aging Cohort Study: study design, baseline characteristics, and prevalence of cognitive impairments. J Alzheimers Dis. 2022;85:561-71.
32. Hao L, Wang X, Zhang L, et al. Prevalence, risk factors, and complaints screening tool exploration of subjective cognitive decline in a large cohort of the Chinese population. J Alzheimers Dis. 2017;60:371-88.
33. Duff K. Evidence-based indicators of neuropsychological change in the individual patient: relevant concepts and methods. Arch Clin Neuropsychol. 2012;27:248-61.
34. Yesavage JA, Brink T, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res. 1982;17:37-49.
37. Gifford KA, Liu D, Romano R 3rd, Jones RN, Jefferson AL. Development of a subjective cognitive decline questionnaire using item response theory: a pilot study. Alzheimers Dement. 2015;1:429-39.
38. Tomaszewski Farias S, Leng I, Papp K, et al. ; U.S. POINTER Study Group. Subjective cognitive decline among diverse older adults: prevalence and associations with objective cognition. Alzheimers Dement. 2025;21:e70432.
39. Gustavson DE, Jak AJ, Elman JA, et al. How well does subjective cognitive decline correspond to objectively measured cognitive decline? Assessment of 10-12 year change. J Alzheimers Dis. 2021;83:291-304.
40. Wolfsgruber S, Kleineidam L, Guski J, et al. ; DELCODE Study Group. Minor neuropsychological deficits in patients with subjective cognitive decline. Neurology. 2020;95:e1134-43.
41. Rosbergen MT, van der Veere P, Claus JJ, et al. Subcortical gray matter volumes and 5‐year dementia risk in individuals with subjective cognitive decline or mild cognitive impairment: a multi‐cohort analysis. Alzheimers Dement. 2025;21:e70413.
42. Melikyan ZA, Al-Darsani Z, Colcord KA, et al. Association of subjective memory complaints with neuropathologic changes at age 90 or older: the 90+ study. Neurology. 2025;105:e213948.
43. Arvanitakis Z, Shah RC, Bennett DA. Diagnosis and management of dementia: review. JAMA. 2019;322:1589-9.
44. Almeida FC, Marx GA, Rohde SK, et al. Cognitive and neuropsychological trajectories in patients with mixed neurodegenerative pathologies. Alzheimers Dement. 2025;21:e70575.
45. Wuestefeld A, Xie L, McGrew E, et al. ; Alzheimer’s Disease Neuroimaging Initiative. Tau, atrophy, and domain-specific cognitive impairment in typical Alzheimer’s disease. Alzheimers Dement. 2025;21:e70511.
46. Brenowitz WD, Hubbard RA, Keene CD, et al. Mixed neuropathologies and associations with domain-specific cognitive decline. Neurology. 2017;89:1773-81.
47. Yu X, Shi R, Zhou X, et al. Correlations between plasma markers and brain Aβ deposition across the AD continuum: Evidence from SILCODE. Alzheimers Dement. 2024;20:6170-82.
48. Márquez F, Tarraf W, Gonzalez K, et al. Alzheimer disease biomarkers and subjective cognitive decline among Hispanic and/or Latino adults. JAMA Netw Open. 2025;8:e2531038.
49. Jack CR Jr, Bennett DA, Blennow K, et al.; Contributors. NIA‐AA Research Framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 2018;14:535-62.
50. Shao K, Hu X, Buerger K, et al. ; DELCODE study group and SILCODE study group. Longitudinal cognitive changes in SCD participants in relation to plasma amyloid status and the potential additive effect of plasma ptau181 levels: a CLoCODE study. Alzheimers Dement. 2025;20:e086729.
51. Kubota M, Bun S, Takahata K, et al. Plasma biomarkers for early detection of alzheimer’s disease: a cross-sectional study in a Japanese cohort. Alzheimers Res Ther. 2025;17:131.
52. Goyal MS, Blazey TM, Su Y, et al. Persistent metabolic youth in the aging female brain. Proc Natl Acad Sci. U S A. 2019;116:3251-5.
